Browsing Tag
Foresite Capital
6 posts
Thyme Care crosses $2bn valuation as $7bn oncology platform expands into new businesses
Thyme Care has secured more than $125 million from Morgan Health, Humana, CVS Health Ventures and other investors at a valuation above $2 billion. The company is already profitable, reaches 10.5 million people and manages more than $7 billion of oncology spending. Its next move is more ambitious: turning the cancer-care platform into a parent company that can attack drug costs, biosimilar adoption and clinical-trial access.
Fulcrum Therapeutics agrees reverse merger with Slate Medicines and $270m dividend
Fulcrum's $270m dividend and 5% stub hand Slate a Nasdaq listing, but SLTE-1009's PACAP bet must beat CGRP incumbents to justify a $350m valuation.
Biogen is paying up to $1bn for preclinical optionality. What does RayThera really add?
Biogen's $1 billion RayThera deal expands its immunology pipeline and raises fresh capital allocation questions. Read what BIIB investors should watch next.
Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million…
ALX Oncology raises $105m to advance clinical development of ALX148
ALX Oncology, a clinical-stage immuno-oncology company based in California, has raised $105 million in a Series C equity…
Element Biosciences raises $80m for genomic sequencing solutions
Californian biotechnology startup Element Biosciences, which focuses on developing genomic sequencing solutions for research and diagnostic markets, has…